ALKS Alkermes
- 24.420
- -0.590-2.36%
Alkermes News
The Analyst Landscape: 7 Takes On Alkermes
During the last three months, 7 analysts shared their evaluations of Alkermes (NASDAQ:ALKS), revealing diverse outlooks from bullish to bearish.The table below provides a concise overview of recent ra
Alkermes Initiated at Buy by TD Cowen
Alkermes Initiated at Buy by TD Cowen
TD Cowen Initiates Alkermes(ALKS.US) With Buy Rating, Announces Target Price $34
TD Cowen analyst Joseph Thome initiates coverage on $Alkermes(ALKS.US)$ with a buy rating, and sets the target price at $34.According to TipRanks data, the analyst has a success rate of 0.0% and a tot
Express News | Alkermes PLC : TD Cowen Initiates Coverage With Buy Rating; Price Target $34
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $35
Mizuho Securities analyst Uy Ear maintains $Alkermes(ALKS.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 37.7% and a total
H.C. Wainwright Maintains Alkermes(ALKS.US) With Hold Rating, Maintains Target Price $35
H.C. Wainwright analyst Douglas Tsao maintains $Alkermes(ALKS.US)$ with a hold rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 38.2% and a t
Jefferies Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $50
Jefferies analyst Akash Tewari maintains $Alkermes(ALKS.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 55.4% and a total av
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
Express News | Alkermes Presents Data From Phase 1B Study of Alks 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at Sleep 2024
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested —— ALKS
Alkermes Shareholders Approve Board Changes and Stock Plan
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN, May 29, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.Jefferies Healthca
Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024PRNewswire– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibran
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations –– Findings Fro
Will Weakness in Alkermes Plc's (NASDAQ:ALKS) Stock Prove Temporary Given Strong Fundamentals?
With its stock down 19% over the past three months, it is easy to disregard Alkermes (NASDAQ:ALKS). However, stock prices are usually driven by a company's financial performance over the long term,
6 Analysts Assess Alkermes: What You Need To Know
Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table encapsulates their recent ratings
Alkermes Is Maintained at Overweight by Cantor Fitzgerald
Alkermes Is Maintained at Overweight by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Alkermes, Raises Price Target to $48
Cantor Fitzgerald Maintains Alkermes(ALKS.US) With Buy Rating, Raises Target Price to $48
Cantor Fitzgerald analyst Charles Duncan maintains $Alkermes(ALKS.US)$ with a buy rating, and adjusts the target price from $36 to $48.According to TipRanks data, the analyst has a success rate of 50.
Analysis
Price Target
No Data
